IRulya Therapeutics Earnings
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics earnings summary
In its most recent report on Nov 13, 2026 (Sep/2026), IRLA posted EPS of $-1.12 versus the $-0.84 consensus estimate, a negative surprise of 33.3%. IRulya Therapeutics beat the consensus EPS estimate in 1 of the last 2 quarters, with a median surprise of +3045.4%. Quarterly EPS is down 100.9% from the same quarter a year earlier.
Across the last 3 reports, IRLA shares moved an average of 0.2% (in either direction) in the first trading session after results, rising 2 times and falling 1 times.
Summary generated from market data by MetaCap's automated system. Methodology
IRLA earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Nov 13, 2026 | $-0.84 | $-1.12 | -33.3% | +0.2% |
| Nov 11, 2026 | $-0.83 | $50.00 | +6124.1% | +0.2% |
| Aug 14, 2026 | — | $-12.31 | — | -0.3% |
| May 11, 2026 | — | $2.88 | — | — |
| Feb 12, 2026 | — | $120.32 | — | — |
| Nov 12, 2025 | — | $-49.83 | — | — |
| Aug 11, 2025 | — | $-68.75 | — | — |
| May 13, 2025 | — | $-3.42 | — | — |
| Mar 24, 2025 | — | $-0.28 | — | — |
| Nov 13, 2024 | — | $-0.13 | — | — |
| Aug 13, 2024 | — | $-0.64 | — | — |
| May 13, 2024 | — | $-0.26 | — | — |
| Apr 1, 2024 | — | $-0.26 | — | — |
| Nov 14, 2023 | — | $-0.15 | — | — |
| Aug 3, 2023 | — | $-0.14 | — | — |
| May 15, 2023 | — | $-0.34 | — | — |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.